secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001437749-22-011511
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q1 revenue $36.2M (+115% YoY); net loss $7.1M vs $1.1M
------------------------------------------------------------------------

- GAAP EPS -$0.17 vs -$0.03; adjusted EBITDA -$814K vs +$2.8M a year ago.
- Organic revenue growth 45%; biopreservation media revenue up 53%.
- Gross margin GAAP 29%, adjusted 33%; improved sequentially from Q4 2021.
- FY22 revenue guidance reaffirmed $159.5-$171M (34-44% growth); expects positive adj. EBITDA.
- Management & board to accept shares in lieu of cash compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000143774922011511/0001437749-22-011511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000143774922011511/bioli20220509_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-011511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer